Healthcare
Grifols, S.A.(GRFS)
Live Price
Offline$7.40
-0.80% today
Window Change
-14.15%
Window
May 6, 2026 β Jun 24, 2026
- Market Cap
- $6.10B
- Revenue Growth
- +0.2%
- EPS Growth
- +147.8%
- Dividend Yield
- 1.7%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 34 bars Β· May 6, 2026 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Grifols, S.A. (GRFS) is a Healthcare stock with a market cap of $6.10B and listed on NASDAQ. The stock last traded around $7.40 and down 14.1% across the available one-year price window (May 6, 2026 β Jun 24, 2026). Baseline metrics include revenue growth of +0.2%, EPS growth of +147.8%, a dividend yield of 1.7%. What stands out right now is revenue +0.2%, EPS +147.8%, free cash flow +41.5% with operating margin 17.0% and ROIC 5.7%. The dividend is present but secondary, with a yield around 1.7%. Valuation is more restrained than many high-expectation growth names at P/E 15.3 and price/sales 0.8. Stock Foundry combines GRFS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.2% vs +7.6% peer median
Operating Margin
Below sector median
+17.0% vs +19.4% peer median
P/E
Below sector median
15.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.2% and EPS at +147.8%, with operating margin around 17.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.7%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
GRFS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GRFS
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GRFS Max Drawdown
-14.63%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GRFS and SPY.
Company Overview
Grifols, S.A.
NASDAQ Global Select
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumΒfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringΒto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
- Leadership
- Jose Ignacio Abia Buenache
- IPO Date
- Jun 2, 2011
- Employees
- 23.8k
- Street Address
- Avinguda de la Generalitat, 152
- Mailing
- Barcelona, 08174
- Region
- Barcelona, ES
- Reporting Currency
- USD
- Investor Line
- 34 93 571 02 21
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.3
- EV/EBITDA
- 10.0
- Price/Sales
- 0.8
- Price/Book
- 1.2
Growth
- Revenue
- +0.2%
- EPS
- +147.8%
- Free Cash Flow
- +41.5%
Profitability
- Gross Margin
- 38.4%
- Operating Margin
- 17.0%
- Net Margin
- 5.3%
- ROE
- 7.6%
- ROIC
- 5.7%
Balance Sheet
- Debt/Equity
- 1.83
- Current Ratio
- 2.51
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.